Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Rating of “Hold” from Brokerages

Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRSGet Free Report) have earned a consensus rating of “Hold” from the seven brokerages that are presently covering the stock, MarketBeat reports. Six research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $22.25.

Separately, StockNews.com lowered Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, April 2nd.

Check Out Our Latest Research Report on ACRS

Aclaris Therapeutics Trading Down 5.9 %

Shares of ACRS opened at $1.11 on Tuesday. Aclaris Therapeutics has a twelve month low of $0.59 and a twelve month high of $11.12. The company’s fifty day simple moving average is $1.21 and its 200-day simple moving average is $1.16. The company has a market cap of $79.10 million, a P/E ratio of -1.02 and a beta of 0.23.

Aclaris Therapeutics (NASDAQ:ACRSGet Free Report) last released its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.04. Aclaris Therapeutics had a negative return on equity of 61.03% and a negative net margin of 248.28%. Analysts predict that Aclaris Therapeutics will post -0.81 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aclaris Therapeutics

Several institutional investors have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Aclaris Therapeutics by 42.6% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 20,317 shares of the biotechnology company’s stock valued at $139,000 after purchasing an additional 6,074 shares during the period. Assenagon Asset Management S.A. raised its stake in Aclaris Therapeutics by 7.9% in the third quarter. Assenagon Asset Management S.A. now owns 687,135 shares of the biotechnology company’s stock worth $4,707,000 after buying an additional 50,306 shares in the last quarter. Barclays PLC lifted its holdings in Aclaris Therapeutics by 174.2% during the third quarter. Barclays PLC now owns 234,150 shares of the biotechnology company’s stock worth $1,603,000 after buying an additional 148,761 shares during the period. Lord Abbett & CO. LLC boosted its position in Aclaris Therapeutics by 14.0% during the 3rd quarter. Lord Abbett & CO. LLC now owns 453,954 shares of the biotechnology company’s stock valued at $3,110,000 after acquiring an additional 55,602 shares in the last quarter. Finally, Algert Global LLC purchased a new position in shares of Aclaris Therapeutics in the 3rd quarter valued at $309,000. Hedge funds and other institutional investors own 98.34% of the company’s stock.

Aclaris Therapeutics Company Profile

(Get Free Report

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.

Read More

Analyst Recommendations for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.